Latest Commercial Readiness News

Jindalee Lithium progresses its McDermitt Lithium Project with strong US government support and a promising new refining technology partnership, aiming to enhance sustainability and reduce costs.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Global Uranium and Enrichment Limited’s investee Ubaryon has sealed a binding agreement with uranium giant Urenco, unlocking a A$5 million investment and technical collaboration to accelerate a novel uranium enrichment technology.

Brazilian Critical Minerals Ltd has reported significant progress at its Ema rare earths project, achieving high recovery rates from in-situ recovery (ISR) tests and securing a $4 million capital raise to accelerate development.

Sovereign Metals’ latest testwork confirms Kasiya graphite’s premium quality amid sweeping US tariffs on Chinese imports, spotlighting its potential as a strategic non-Chinese supply source for battery manufacturers.

Brazilian Critical Minerals reports exceptional pilot field trial results at its Ema rare earth project, advancing permitting and feasibility studies while attracting strong market interest.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

ClearVue Technologies’ solar façade trial at Hong Kong EMSD headquarters reveals a rapid 2.6-year payback period with government incentives, alongside strong thermal and fire safety performance.

Global Uranium and Enrichment Limited is on the verge of finalizing a strategic partnership with uranium enrichment giant Urenco, securing a $5 million investment to accelerate Ubaryon’s innovative technology development.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Hawsons Iron Limited is raising up to $1 million through a discounted Share Purchase Plan to fund critical project development while continuing strategic investor discussions.